News Image

MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy

Provided By GlobeNewswire

Last update: Jul 15, 2025

NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies, today announced the publication of a peer-reviewed article titled “CAR-iNKT Cells: Redefining the Frontiers of Cellular Immunotherapy” in Frontiers in Immunology. The publication, authored by leading experts in iNKT biology, underscores the power of iNKT cells as the next-generation off-the-shelf platform for treating solid tumors—where conventional cell therapies have failed to deliver lasting results.

Read more at globenewswire.com